← 產業報告目錄
Rituximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, By Application, By Route of Administration, By Molecule Type, By Distribution Channel Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-09頁數 180報告編號 INSIGHTACE-c13df0b78a
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Across the 2025 to 2034 projection horizon, the worldwide Rituximab Biosimilar Market is expected to register a CAGR of 12.3%.
At its core, Rituximab Biosimilar pertains to a chimeric anti-cd20 antibody that binds to the cd20 antigen present on the standard and malignant b cells surface. Stakeholders across the healthcare landscape are mountingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened call for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region expected to deliver the strongest growth trajectory through the forecast period, propelled by demographic shifts and policy support.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Rituximab Biosimilar Market Snapshot
Chapter 4. Global Rituximab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Dynamics - Drivers
4.3. Challenges/Restraints
4.4. Market Trends
4.5. Industry Analysis – Porter's Five Forces Analysis
4.6. Clinical Trials/Pipeline Analysis -2019
4.7. Historic Revenue of Originator Drug: MabThera / Rituxan (rituximab)
4.8. COVID 19 Impact on Pharmaceutical Industry
Chapter 5. Market Segmentation 1: Application Estimates & Trend Analysis
5.1. Application & Market Share, 2024 & 2034
5.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
5.2.1. Riabni
5.2.2. Rituxan
5.2.3. Rituxan Hycela
5.2.4. Ruxience
5.2.5. Truxima
5.2.6. Riximyo
5.2.7. Truxima
5.2.8. Rixathon
5.2.9. Blitzima
5.2.10. Ruxience
5.2.11. Ituxredi
5.2.12. Others (Products approved in developing countries & pipeline products)
Chapter 6. Market Segmentation 2: Route Of Administration Estimates & Trend Analysis
6.1. Application & Market Share, 2024 & 2034
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
6.2.1. Subcutaneous
6.2.2. Intravenous
6.2.3. Parenteral
6.2.4. Molecule Type
Chapter 7. Market Segmentation 3: Molecule Type Estimates & Trend Analysis
7.1. Application & Market Share, 2024 & 2034
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:
7.2.1. Monoclonal antibodies
7.2.2. Peptide
7.2.3. Protein
7.2.4. Small molecule
7.2.5. Product Type
Chapter 8. Rituximab Biosimilar Market Segmentation 4: Distribution Channels Estimates & Trend Analysis
8.1. Distribution Channels Analysis & Market Share, 2024 & 2034
8.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channels:
8.2.1. Hospital Pharmacy
8.2.2. Online Pharmacy
8.2.3. Retail Pharmacy
8.2.4. Other Direct Distribution Channels
Chapter 9. Rituximab Biosimilar Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.1.2. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.1.3. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.1.4. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.1.5. North America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
9.1.5.1. U.S.
9.1.5.2. Canada
9.2. Europe
9.2.1. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.2.2. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.2.3. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.2.4. Europe Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.2.5. Europe Rituximab Biosimilar Market revenue (US$ Million) by country, 2021-2034
9.2.5.1. Germany
9.2.5.2. Poland
9.2.5.3. France
9.2.5.4. Italy
9.2.5.5. Spain
9.2.5.6. UK
9.2.5.7. Rest of Europe
9.3. Asia Pacific
9.3.1. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.3.2. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.3.3. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.3.4. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.3.5. Asia Pacific Rituximab Biosimilar Market revenue (US$ Million) by country, 2021-2034
9.3.5.1. China
9.3.5.2. India
9.3.5.3. Japan
9.3.5.4. Australia
9.3.5.5. Rest of Asia Pacific
9.4. Latin America
9.4.1. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.4.2. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.4.3. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.4.4. Latin America Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.4.5. Latin America Rituximab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.4.5.1. Brazil
9.4.5.2. Rest of Latin America
9.5. MEA
9.5.1. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Application, 2021-2034
9.5.2. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
9.5.3. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Molecule type, 2021-2034
9.5.4. MEA Rituximab Biosimilar Market revenue (US$ Million) estimates and forecasts by Distribution Channels, 2021-2034
9.5.5. MEA revenue Rituximab Biosimilar Market revenue (US$ Million) by country, (US$ Million) 2021-2034
9.5.5.1. South Africa
9.5.5.2. Rest of MEA
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances in Biosimilar Industry
10.2. Company Profiles
10.2.1. Amgen Inc.
10.2.1.1. Company Overview
10.2.1.2. Financials
10.2.1.3. Rituximab Product Portfolio - ABP 798
10.2.1.4. Business Strategy & Recent Developments
10.2.2. GENENTECH
10.2.3. Pfizer Inc.
10.2.4. Celltrion, Inc.
10.2.5. Sandoz GmbH
10.2.6. Sandoz GmbH
10.2.7. Dr. Reddy's Laboratories
10.2.8. Biocad
10.2.9. Shanghai Henlius Biotech
10.2.10. AryoGen Pharmed
10.2.11. Laboratorios PiSA
10.2.12. Other prominent players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們